MADISON, NJ – Merck Animal Health has announced that Bovilis® Nasalgen® 3-PMH is now available to veterinarians and cattle producers to protect cattle from five of the most common pneumonia-causing viral and bacterial pathogens. Approved for use in dairy and beef cattle, this is the first intranasal vaccine effective in providing early, broad-spectrum respiratory protection against both viral and bacterial pathogens in a needle free, animal- and BQA-friendly administration.
“Bovilis Nasalgen 3-PMH is a modified-live, intranasal vaccine that stimulates a strong early immune response to help give calves a strong foundation of respiratory disease protection,” says Scott Nordstrom, D.V.M., director of livestock innovation and discovery, Merck Animal Health. “Results of efficacy, duration of immunity and safety studies demonstrate the vaccine is safe and effective for calves at 1 week of age or older.”
The vaccine, which protects against infectious bovine rhinotracheitis (IBR), bovine respiratory syncytial virus (BRSV), parainfluenza 3 (PI3), Mannheimia haemolytica and Pasteurella multocida, is administered in a single 2-mL dose. It contains a unique BluShadowTM diluent that clearly indicates which animals have been vaccinated. With needle-free intranasal administration, the vaccine meets best management practices outlined in the industry’s Beef Quality Assurance program.
Bovilis Nasaslgen 3-PMH is proven safe for use in pregnant cows and in calves nursing pregnant cows, as well as young calves. It is available in 2-mL, 20-mL and 100-mL packages. Consult your veterinarian for specific usage guidance.
The availability of Bovilis Nasaslgen 3-PMH follows the company’s launch in early 2020 of Bovilis® Nasalgen® 3. Both of these modified-live, intranasal vaccines stimulate a strong early immune response to help give calves a solid foundation of respiratory disease protection.
Studies demonstrate that Bovilis® Nasalgen 3-PMH has the following duration of immunity: IBR of at least 195 days, BRSV of at least 78 days, PI3 of at least 95 days, M. haemolytica of at least 122 days and P. multocida of at least 125 days.
Both Bovilis® Nasalgen 3 and Bovilis® Nasalgen 3-PMH contain a unique BluShadow® diluent that clearly indicates which animals have been vaccinated. Nasalgen 3 and Nasalgen 3-PMH also are:
• Approved safe for use in pregnant cows or in calves nursing pregnant cows
• Administered in a single 2-mL dose that is easy to administer
• Given with a needle-free intranasal administration that meets best management practices outlined in the industry’s Beef Quality Assurance program
For more information on Bovilis® Nasalgen 3-PMH go to www.Nasalgen.com.
###
About Merck Animal Health
For more than a century, Merck, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Merck Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA, is the global animal health business unit of Merck. Through its commitment to the Science of Healthier Animals®, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of digitally connected identification, traceability and monitoring products. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com or connect with us on LinkedIn, Facebook, and Twitter at @MerckAH. Visit Merck at World Ag Expo® Online at http://bit.ly/WAE21-MerckAH.